Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant gliomas.

E C Burton1, M D Prados

  • 1Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus 808A, San Francisco, CA, 94143-0372, USA.

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Acute renal failure secondary to haemorrhagic acute pancreatitis with normal serum amylase levels].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia·2007
Same author

Successful kidney transplantation reduces hyperplastic parathyroid gland.

Transplantation proceedings·2007
Same author

Overestimation of clinical diagnostic performance caused by low necropsy rates.

Quality & safety in health care·2005
Same author

[Acute obstructive renal failure secondary to retroperitoneal mass].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia·2004
Same author

The autopsy as an outcome and performance measure.

Evidence report/technology assessment (Summary)·2002
Same author

Age and radiation response in glioblastoma multiforme.

Neurosurgery·2002
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

High-grade gliomas require surgery, radiation, and chemotherapy. Maximal resection improves outcomes, and specific chemotherapy regimens like PCV show promise for certain anaplastic oligodendrogliomas with 1p/19q loss.

Area of Science:

  • Neuro-oncology
  • Neurosurgery
  • Radiation Oncology

Background:

  • Gliomas are the most common primary brain tumors in adults.
  • High-grade gliomas include anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), and anaplastic oligodendroglioma (AO).
  • Mixed lineage tumors like anaplastic oligoastrocytoma (AOA) also occur.

Purpose of the Study:

  • To outline the standard and emerging treatment strategies for adult high-grade gliomas.
  • To discuss the role of surgery, radiation, and chemotherapy in managing these CNS neoplasms.
  • To highlight prognostic factors and patient-specific treatment considerations.

Main Methods:

  • Maximal safe surgical resection for diagnosis and improved outcomes.
  • Postsurgical radiation therapy as a standard survival-improving treatment.

Related Experiment Videos

  • Adjuvant chemotherapy, including BCNU and PCV regimens, with consideration for patient age and tumor molecular markers.

    • Main Results:

    • Aggressive surgical resection enhances survival and neurologic function.
    • Postsurgical irradiation is the most effective current treatment for survival.
    • Chemotherapy offers modest benefits, particularly in younger patients and specific molecular subtypes (e.g., 1p/19q-deleted AO with PCV).

    Conclusions:

    • Multimodal therapy including surgery, radiation, and chemotherapy is standard for high-grade gliomas.
    • Tumor molecular characteristics, such as 1p/19q codeletion, significantly impact treatment response and prognosis.
    • Personalized treatment approaches, considering patient factors and tumor biology, are crucial for optimizing outcomes in glioma management.